Market Eyes LiveViatris Inc. (VTRS) Stock Rating & Analysis
MELANY's data-driven read on Viatris Inc. · Pharmaceutical Preparations.
Viatris was created in November 2020 by combining Upjohn, a Pfizer subsidiary specializing in off-patent drugs, with Mylan, a global generic and specialty drug maker. The combination made Viatris one of the largest generic drug manufacturers in the world, serving over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of total sales; the other 60% comes from legacy products including Lipitor, Norvasc, Lyrica, and Viagra.
Why VTRS scores 70/100
MELANY scores Viatris Inc. 70/100 by weighing eight factors. Here is how VTRS breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- PEG ratio 1.05 (< 1 = undervalued)
- FCF yield 13.9%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 40%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +10%
What Wall Street price targets and revisions are signalling.
- Institutional net buying +5.4%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for VTRS
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Viatris Inc. sits in the Healthcare sector theme, which MELANY currently rates 55/100 for strength. Theme strength feeds VTRS's momentum and catalyst factors above.
VTRS trade plan (members only)
MELANY has a full position plan for Viatris Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates VTRS
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Viatris Inc.'s 70/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about VTRS
Is Viatris Inc. (VTRS) a buy?
As of 2026-08-25, MELANY rated Viatris Inc. Highest Conviction with a composite score of 70/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Viatris Inc.'s MELANY score?
Viatris Inc. (VTRS) has a MELANY composite score of 70/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the VTRS stock rating calculated?
MELANY scores VTRS from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Viatris Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Viatris Inc. (VTRS) Highest Conviction with a composite of 70/100 as of 2026-08-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the VTRS stock price forecast?
MELANY does not publish price targets or forecasts for VTRS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 70/100 across eight factors for Viatris Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is VTRS stock overvalued or undervalued?
MELANY's valuation factor currently reads 94/100 for Viatris Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives VTRS's read.
What price should I buy VTRS at?
Rather than chasing the current price, MELANY computes a smart entry zone for VTRS: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying VTRS stock?
The top risks MELANY currently flags for Viatris Inc.: No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Viatris Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 42/100 for Viatris Inc., and earnings track record, at 89/100. The 70/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will VTRS stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 69/100 for VTRS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this VTRS rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores VTRS continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
VTRS's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.